(Cisplatin + vinblastine sulphate) is under clinical development by Intensity Therapeutics and currently in Phase II for Metastatic Pancreatic Cancer. According to GlobalData, Phase II drugs for Metastatic Pancreatic Cancer have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Cisplatin + vinblastine sulphate)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Cisplatin + vinblastine sulphate) overview
Cisplatin in a fixed dose combination with vinblastine sulfate (INT-2306) is under development for the treatment of solid tumors, melanoma, lymphoma, head and neck, liver, chordoma, metastatic colorectal cancer, cutaneous squamous cell carcinoma, lung, metastatic pancreatic, ovarian, thyroid, colon, metastatic hepatocellular carcinoma, triple negative breast cancer, breast cancer, soft tissue sarcomas, glioblastoma multiforme and bile duct cancer. The drug candidate is administered intratumorally and intravenously. The drug candidate is developed based on intratumoral amphiphilic solutions technology.
Intensity Therapeutics overview
Intensity Therapeutics is a clinical-stage biotechnology company that focuses on human clinical testing to treat refractory solid tumor cancers. The company is headquartered in Fairfield, Connecticut, the US.
For a complete picture of (Cisplatin + vinblastine sulphate)’s drug-specific PTSR and LoA scores, buy the report here.